Divi's Laboratories Overview

  • Year Founded
  • 1990

Year Founded

  • Status
  • Public

  • Employees
  • 9,634

Employees

  • Stock Symbol
  • DIVISLAB

Stock Symbol

  • Share Price
  • $119.59
  • (As of Thursday Closing)

Divi's Laboratories General Information

Description

Divi's Laboratories Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical Ingredients, with predominance in exports. Through its custom synthesis business, the Company supports innovator pharma companies for patented products from gram-scale requirements for clinical trials to launch and late-life cycle management, in addition to generics. It operates in a single operating segment, Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceutical Ingredients. The Company derives maximum revenue from Europe.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Divi Towers, Cyber Hills
  • Gachibowli
  • Hyderabad, 500032
  • India
+91 040
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NSE
Corporate Office
  • Divi Towers, Cyber Hills
  • Gachibowli
  • Hyderabad, 500032
  • India
+91 040

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Divi's Laboratories Stock Performance

As of 19-Nov-2026, Divi's Laboratories’s stock price is $119.59. Its current market cap is $31.7B with 265M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$119.59 $118.20 $60.96 - $125.90 $31.7B 265M 630K $1.37

Divi's Laboratories Financials Summary

As of 30-Sep-2026, Divi's Laboratories has a trailing 12-month revenue of $1.31B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 25,343,893 16,321,103 17,471,189 10,538,039
Revenue 1,314,833 1,185,554 1,102,804 941,707
EBITDA 536,244 406,275 357,746 270,940
Net Income 362,709 290,617 259,114 193,270
Total Assets 2,286,697 2,123,206 1,979,441 1,855,061
Total Debt 625 742 468 360
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Divi's Laboratories Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Divi's Laboratories‘s full profile, request access.

Request a free trial

Divi's Laboratories Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Divi's Laboratories Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nu
Drug Discovery
Hyderabad, India
9,634 As of 2026

Ahmedabad, India
 

Hyderabad, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Divi's Laboratories Competitors (15)

One of Divi's Laboratories’s 15 competitors is Zydus Lifesciences, a Corporation company based in Ahmedabad, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zydus Lifesciences Corporation Ahmedabad, India
Aurobindo Pharma Corporation Hyderabad, India
Wockhardt Corporation Mumbai, India
Anthem Biosciences Formerly PE-Backed Bengaluru, India
Sun Pharmaceutical Industries Corporation Mumbai, India
You’re viewing 5 of 15 competitors. Get the full list »

Divi's Laboratories Patents

Divi's Laboratories Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4763856-A1 Process for the preparation of fmoc-gly-thr [psi (me, me) pro]-oh Pending 17-Dec-2024
US-20260167668-A1 Process for the preparation of fmoc-gly-thr [psi (me, me) pro]-oh Pending 17-Dec-2024
EP-4282971-A1 An improved process for the preparation of (r )-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam Pending 23-May-2022
JP-7402935-B2 An improved process for the preparation of (r)-4-propylpyrrolidin-2-one, a key intermediate for the synthesis of brivaracetam. Active 23-May-2022
JP-2023172821-A Improved process for preparation of (r)-4-propyl pyrrolidine-2-one, key intermediate for synthesis of brivaracetam Active 23-May-2022 C12P7/62
To view Divi's Laboratories’s complete patent history, request access »

Divi's Laboratories Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Divi's Laboratories Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Divi's Laboratories‘s full profile, request access.

Request a free trial

Divi's Laboratories ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

31.25 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Divi's Laboratories’s complete esg history, request access »

Divi's Laboratories FAQs

  • When was Divi's Laboratories founded?

    Divi's Laboratories was founded in 1990.

  • Where is Divi's Laboratories headquartered?

    Divi's Laboratories is headquartered in Hyderabad, India.

  • What is the size of Divi's Laboratories?

    Divi's Laboratories has 9,634 total employees.

  • What industry is Divi's Laboratories in?

    Divi's Laboratories’s primary industry is Drug Discovery.

  • Is Divi's Laboratories a private or public company?

    Divi's Laboratories is a Public company.

  • What is Divi's Laboratories’s stock symbol?

    The ticker symbol for Divi's Laboratories is DIVISLAB.

  • What is the current stock price of Divi's Laboratories?

    As of 19-Nov-2026 the stock price of Divi's Laboratories is $119.59.

  • What is the current market cap of Divi's Laboratories?

    The current market capitalization of Divi's Laboratories is $31.7B.

  • What is Divi's Laboratories’s current revenue?

    The trailing twelve month revenue for Divi's Laboratories is $1.31B.

  • Who are Divi's Laboratories’s competitors?

    Zydus Lifesciences, Aurobindo Pharma, Wockhardt, Anthem Biosciences, and Sun Pharmaceutical Industries are some of the 15 competitors of Divi's Laboratories.

  • What is Divi's Laboratories’s annual earnings per share (EPS)?

    Divi's Laboratories’s EPS for 12 months was $1.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process